Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Xeris Biopharma in a research report issued on Tuesday, August 12th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of $0.01 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma's Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.02) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS, FY2028 earnings at $0.54 EPS and FY2029 earnings at $0.76 EPS.
Several other analysts have also commented on the stock. Oppenheimer raised their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Xeris Biopharma currently has a consensus rating of "Moderate Buy" and an average target price of $6.58.
Check Out Our Latest Research Report on XERS
Xeris Biopharma Stock Up 1.6%
Shares of XERS stock traded up $0.1150 on Thursday, hitting $7.4750. The company had a trading volume of 1,020,433 shares, compared to its average volume of 2,567,973. The firm has a market cap of $1.21 billion, a P/E ratio of -35.59 and a beta of 0.65. The company has a 50-day moving average price of $5.28 and a 200-day moving average price of $4.75. Xeris Biopharma has a twelve month low of $2.48 and a twelve month high of $7.79.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million.
Institutional Investors Weigh In On Xeris Biopharma
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its position in Xeris Biopharma by 92.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock worth $172,000 after purchasing an additional 14,986 shares during the last quarter. Millennium Management LLC increased its position in Xeris Biopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after purchasing an additional 502,853 shares during the last quarter. Geode Capital Management LLC increased its position in Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock worth $11,364,000 after purchasing an additional 17,956 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Xeris Biopharma during the fourth quarter worth about $47,000. Finally, Raymond James Financial Inc. acquired a new stake in Xeris Biopharma during the fourth quarter worth about $45,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Xeris Biopharma
In other Xeris Biopharma news, insider Kevin Mcculloch purchased 25,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were purchased at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the purchase, the insider owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This represents a 1.48% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Dawn Halkuff sold 42,500 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares in the company, valued at approximately $837,200. This represents a 26.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.47% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Further Reading
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access